Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D, Polerà N, Belmonte B, Conforti F, Signorelli S, Gulino A, Staropoli N, Tuccillo FM, Bonelli P, Juli G, Grillone K, Ascrizzi S, Cirillo M, Migale L, Ballerini A, Pelizon C, Di Martino MT, Tagliaferri P, Riillo C, Tassone P. Caracciolo D, et al. Among authors: gulino a. Br J Haematol. 2024 Feb;204(2):555-560. doi: 10.1111/bjh.19183. Epub 2023 Nov 14. Br J Haematol. 2024. PMID: 37963444
Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer.
Mangogna A, Belmonte B, Agostinis C, Ricci G, Gulino A, Ferrara I, Zanconati F, Tripodo C, Romano F, Kishore U, Bulla R. Mangogna A, et al. Among authors: gulino a. Front Immunol. 2018 Aug 6;9:1748. doi: 10.3389/fimmu.2018.01748. eCollection 2018. Front Immunol. 2018. PMID: 30127783 Free PMC article.
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D, Riillo C, Ballerini A, Gaipa G, Lhermitte L, Rossi M, Botta C, Duroyon E, Grillone K, Gallo Cantafio ME, Buracchi C, Alampi G, Gulino A, Belmonte B, Conforti F, Golino G, Juli G, Altomare E, Polerà N, Scionti F, Arbitrio M, Iannone M, Martino M, Correale P, Talarico G, Ghelli Luserna di Rorà A, Ferrari A, Concolino D, Sestito S, Pensabene L, Giordano A, Hildinger M, Di Martino MT, Martinelli G, Tripodo C, Asnafi V, Biondi A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: gulino a. J Immunother Cancer. 2021 Feb;9(2):e002026. doi: 10.1136/jitc-2020-002026. J Immunother Cancer. 2021. PMID: 33597219 Free PMC article.
Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma.
Belmonte B, Cancila V, Gulino A, Navari M, Arancio W, Macor P, Balduit A, Capolla S, Morello G, Vacca D, Ferrara I, Bertolazzi G, Balistreri CR, Amico P, Ferrante F, Maiorana A, Salviato T, Piccaluga PP, Mangogna A. Belmonte B, et al. Among authors: gulino a. Cancers (Basel). 2021 Jun 12;13(12):2958. doi: 10.3390/cancers13122958. Cancers (Basel). 2021. PMID: 34204843 Free PMC article.
Direct RNA Nanopore Sequencing of SARS-CoV-2 Extracted from Critical Material from Swabs.
Vacca D, Fiannaca A, Tramuto F, Cancila V, La Paglia L, Mazzucco W, Gulino A, La Rosa M, Maida CM, Morello G, Belmonte B, Casuccio A, Maugeri R, Iacopino G, Balistreri CR, Vitale F, Tripodo C, Urso A. Vacca D, et al. Among authors: gulino a. Life (Basel). 2022 Jan 4;12(1):69. doi: 10.3390/life12010069. Life (Basel). 2022. PMID: 35054462 Free PMC article.
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C. Iannitto E, et al. Among authors: gulino a. Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8. Br J Haematol. 2018. PMID: 30407629 Free article. Clinical Trial.
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovì S, Puleio R, Cassata G, Gulino A, Belmonte B, Gramignoli R, Strom SC, McCubrey JA, Montalto G, Cervello M. Augello G, et al. Among authors: gulino a. Int J Cancer. 2019 May 15;144(10):2613-2624. doi: 10.1002/ijc.31963. Epub 2018 Dec 24. Int J Cancer. 2019. PMID: 30488605 Free article.
419 results